Amendments for: 172-2023-2024-Q2-1009921

Current (Nov 16, 2023)

Agreement Value: $320,000.00
Agreement: Elarex VSV and Adv Viral Vector Vaccines Stabilization (1009921). Jun 1, 2023 - Jun 30, 2024
Description:

Stabilization of multiple viral vector platforms with PT120-D to produce strong preclinical evidence of impact.

Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

This agreement has been amended 1 time(s). The end date of this agreements has been modified by 91 days.

Recipient's Operating Name: Elarex
Federal Riding Name: Burlington (35015)
Program Name: Industrial Research Assistance Program – Contributions to Firms

Coverage: IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code: 54171

Amendment 01 (Nov 16, 2023)

Agreement Value:
Organization: National Research Council Canada
Recipient: -
Type: -
Additional Information:

This agreement has been amended 1 time(s). The end date of this agreements has been modified by 91 days.

Amendment 00

Agreement Value: $320,000.00
Agreement: Elarex VSV and Adv Viral Vector Vaccines Stabilization (1009921). Jun 1, 2023 - Mar 31, 2024
Description:

Stabilization of multiple viral vector platforms with PT120-D to produce strong preclinical evidence of impact.

Expected Results:

Organization: National Research Council Canada
Recipient: ELAREX INC. (For-profit organization)
Location: Burlington, Ontario, CA L7L 4X5
Type: Contribution
Recipient's Operating Name: Elarex
Federal Riding Name: Burlington (35015)
Program Name: Industrial Research Assistance Program – Contributions to Firms

Coverage: IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code: 54171